Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

MonlunabantAlso known as INV-202

So-called peripheral CB1 inverse agonist; 2025 phase 2a: weight loss of 6.4 to 8.0 kg versus placebo, with dose-dependent withdrawals for adverse events.

Level of detail

C₂₆H₂₂ClF₃N₆O₃S

CAS 2712480-46-9

Family
ECS pharmacological toolAntagonist or inverse agonist
Molar mass
591.00 g/mol

Updated on

In plain terms

Monlunabant blocks the CB1 receptor, as rimonabant did, a drug that was abandoned because its use was associated with negative mood and suicidal thoughts. It was designed not to enter the brain, but a mouse study suggests it acts there. A 2025 trial in adults with obesity showed weight loss versus placebo, with adverse effects (nausea, anxiety) that rise with the dose.

Receptors and activity

Target network

CB1Inverse agonistCB1 inverse agonist; binding at the orthosteric site (cryo-EM); bias towards β-arrestin 2 inhibition over Gi; affinity value not found in the sources read (Kumari et al. 2024); peripheral restriction disputed in the mouse (Mullassaril et al. 2025)
  • Blocks or inhibits

The lower the cited value, the closer the target sits to Monlunabant: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of Monlunabant.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1Inverse agonistno measured value cited

    CB1 inverse agonist; binding at the orthosteric site (cryo-EM); bias towards β-arrestin 2 inhibition over Gi; affinity value not found in the sources read (Kumari et al. 2024); peripheral restriction disputed in the mouse (Mullassaril et al. 2025)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Measured effects

Not characterised. No placebo-controlled human trial has measured the effects of Monlunabant, so no level is shown.

Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method

Pharmacology

Monlunabant is a CB1 receptor inverse agonist designed to act in the periphery. It answers a question raised by the discontinuation of rimonabant, whose use was occasionally associated with negative affect and suicidality (Meye et al. 2013): does the metabolic benefit of CB1 blockade come from peripheral receptors? The phase 2a trial published in 2025 by Knop and colleagues, double-blind against placebo, lasted 16 weeks in 243 adults with obesity and metabolic syndrome at 25 Canadian centres (10, 20 or 50 mg a day by mouth). At week 16, the weight difference versus placebo was −6.4 kg (10 mg), −6.9 kg (20 mg) and −8.0 kg (50 mg), the loss being only slightly greater at higher doses. Adverse events, mostly gastrointestinal and psychiatric, were dose dependent: 69%, 78% and 92% of participants against 69% on placebo; withdrawals for adverse events reached 13%, 27% and 42% against none on placebo, owing to nausea, anxiety, diarrhoea, irritability and sleep disorder. No deaths were reported, and the authors consider that lower doses need evaluation (Knop et al. 2025). In mice, monlunabant reduces appetite and blocks HU-210-induced hypothermia at the same doses, pointing to an action on central CB1 (Mullassaril et al. 2025).

History

Source
An entirely synthetic compound with no natural occurrence. It comes from a pharmaceutical development programme; no commercialisation was found.

Origin

Research tool

No biological pathway: monlunabant is a synthetic compound of the dihydropyrazole (pyrazoline) class bearing a sulfonylated acylguanidine, unrelated to the plant cannabinoid pathway.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Antagonist or inverse agonist

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

Monlunabant (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

Common name
Monlunabant (INV-202)
IUPAC name
N-[(E)-N'-[(E)-C-[(4S)-5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]-N-[4-(trifluoromethyl)phenyl]sulfonylcarbonimidoyl]carbamimidoyl]acetamide
Other names
INV-202 · MRI-1891 · monlunabantum

Identifiers

Formula
C₂₆H₂₂ClF₃N₆O₃S
CAS
2712480-46-9
InChIKey
GYJPQNPVIJXXTA-JOCHJYFZSA-N
SMILES
CC(O)=NC(=N)N=C(NS(=O)(=O)c1ccc(C(F)(F)F)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.